MONTREAL, QUEBEC--(CCNMatthews - May 2, 2005) - Paladin Labs Inc.
(TSX:PLB), a leading Canadian specialty pharmaceutical company, today
announced that it has entered into a Canadian marketing and supply
agreement with Watson Pharma, Inc., a subsidiary of Watson
Pharmaceuticals, Inc. (NYSE:WPI) to market Trelstar(R) 3.75 mg and
Trelstar(R) LA 11.25 mg (triptorelin pamoate for injectable suspension).
Trelstar(R) 3.75 mg, 1 month slow release, is an injectable,
luteinizing hormone-releasing hormone (LHRH) agonist indicated for the
palliative treatment of advanced prostate cancer and for the treatment
of endometriosis. Trelstar(R) LA 11.25 mg, 3 month slow release, is an
injectable, luteinizing hormone-releasing hormone (LHRH) agonist
indicated for the palliative treatment of advanced prostate cancer.
Trelstar(R) 3.75 mg and Trelstar(R) LA 11.25 mg are approved for sale in
Canada.
